Abstract: The invention relates to a process for the preparation of a tablet or dragee composition containing a moisture-, heat- and light-sensitive compounds having monoclinic crystalline structure as active ingredients, which comprises homogenizing the active ingredient with 0.2 to 1.5 parts by weight of an anhydrous alkaline earth metal salt and 0.5 to 2.5 parts by weight of microcrystalline cellulose calculated for the active ingredient and optionally with one or more pharmaceutically acceptable carrier(s) and/or additive(s) and compressing the homogeneous mixture obtained to tablets in a manner known per se and, if desired, coating the tablet thus obtained in a manner known per se.

Abstract: The invention relates to a process for the preparation of 1-(3-chlorophenyl)-4-methyl-7,8-dimethoxy-5 H-2,3-benzodiazepine of formula (I) ##STR1## in high purity and in a quality suitable for pharmaceutical purposes. According to the invention the reaction of 1 mole of 2-acetonyl-3'-chloro-4,5-dimethoxybenzophenone of formula (II) ##STR2## with 3-7 moles of hydrazine hydrate in an organic solvent or in a mixture of organic solvents at a temperature between 15.degree. C. and 85.degree. C. is carried out in the absence of air oxygen, optionally in the presence of water. The crude product is then recrystallized from an aliphatic alcohol containing 1 to 5 carbon atom(s).

Abstract: The invention relates to a novel oil-in-water type cream containing aluminum potassium sulfate, which is useful for the treatment of varicosity. The composition of the invention contains 1 to 15% by weight of pharmaceutically acceptable lipid-type ointment base, 0 to 10% by weight of aluminum potassium sulfate dissolved in water, 10 to 80% by weight of propylene glycol and 0.1 to 5.0% by weight of cetyltrimethylammonium bromide and/or cetyltrimethylammonium chloride as emulsifying agent.

Abstract: The present invention relates to an intravenous pharmaceutical composition comprising cyclosporin as active ingredient. The composition is composed ofa) 1 part by mass of one or more cyclosporins,b) 8 to 13 parts by mass of a monoester of a saturated hydroxylated fatty acid formed with polyethylene glycol or the mixture of said monoesters,c) 4 to 10 parts by mass of one or more intravenously administerable mono- or polivalent alcohols.The invention further relates to a process for preparing such composition.

Abstract: Pharmaceutical compositions for sustained release of pharmaceutical compounds comprising a reaction product of a water soluble salt of a pharmaceutically active compound containing a primary, secondary or tertiary amino group, and an alkali or ammonium salt of a synthetic copolymer containing an acid group, and selected from the group consisting of methacrylic acid/methacrylic acid methyl ester, methacrylic acid/acrylic acid methyl ester and methacrylic acid/acrylic acid methyl ester/methacrylic acid methyl ester copolymers and a pharmaceutically acceptable excipient. The water soluble salt of a pharmaceutically active compound containing a primary, secondary or tertiary amino group is reacted in aqueous medium with an alkali or ammonium salt of a copolymer selected from the group consisting of the above mentioned copolymers, and the resulting product is converted into a pharmaceutical composition.